Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 StudyLeslie S. Kean, Susan DeWolf, Sung Won Choi et al.|Blood|2023Cited by 12
<i>Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia</i>Gail J. Roboz, Naveen Pemmaraju, Daniel J. DeAngelo et al.|Blood|2020Cited by 11
Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic TransplantationNelli Bejanyan, Marco L. Davila, Hany Elmariah et al.|Blood|2024Cited by 2
Phase I Trial of Ex Vivo Expanded Donor Gamma Delta T Cell Immunotherapy to Prevent Acute Myeloid Leukemia Relapse after Allogeneic TransplantationNelli Bejanyan, Marco L. Davila, Hany Elmariah et al.|Transplantation and Cellular Therapy|2025Cited by 1
Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant OutcomesLuis E. Aguirre, Maximilian Stahl, Haesook T. Kim et al.|Blood|2024Cited by 0